KRTClinical Trials•globenewswire•
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Sentiment:Positive (72)
Summary
(NASDAQ:KRT) Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 31, 2025 by globenewswire